Cancers are unique and often described as a "moving target" because they are complex and dynamic diseases that constantly evolve, changing behavior to adapt and effectively evade treatments.
Our programs are focused on a new generation of precision drugs for cancer treatment that target multiple cancer-associated processes simultaneously based on the characteristics of the tumor and patients’ genes.
AFX-1099 is an early clinical-stage small molecule for treatment of glioblastoma. Initial human study data indicates that AFX-1099, as an adjunctive treatment post-tumor resection, was significantly effective in reducing recurrent or residual tumor without toxic side effects or damage to surrounding normal tissue. AFX-1099 is now undergoing formulation into a novel engineered nanomaterial to be used post-tumor resection.
AFX-125 is a mid-stage, preclinical lead from a series of new chemical entities that inhibit multiple pathways associated with malignant melanoma. In several different melanoma cell lines, AFX-125 inhibited cell growth by simultaneously acting on multiple cancer-associated pathways without toxicity to normal cells.
References:
- Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents. Cell Commun Signal 22, 228 (2024). https://doi.org/10.1186/s12964-024-01607-9